Safety of Formalin-free Fixatives for In-Vivo Fixation of Skin Lesions.
Recruitment status was: Not yet recruiting
|Skin Abnormality||Device: Formulations for in-vivo fixation||Early Phase 1|
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
|Official Title:||Safety of Formalin-free Fixatives for In-Vivo Fixation of Skin Lesions.|
- Safety [ Time Frame: One year ]Infiltration of formulations into skin lesions.
- Safety of formulations [ Time Frame: One year ]Infiltration of the formulations into skin lesions with resultant in-vivo fixation and the achievement of histological result. Possible local pain, infection and scarring will be evaluated.
|Study Start Date:||December 2010|
|Estimated Study Completion Date:||May 2012|
|Estimated Primary Completion Date:||May 2011 (Final data collection date for primary outcome measure)|
Experimental: Skin lesions
Individuals with skin lesions whose lesions are not sent for histology by dermatologists
Device: Formulations for in-vivo fixation
Formulations are comprised of non-toxic ingredients used in dermatology.
Other Name: Formulation ingredients:
The formulations are comprised of standard non-toxic laboratory chemicals that are used in various dermatological preparations.
Transition metal salts - Zinc chloride, zinc bromide, zinc iodide,zinc nitrate, zinc sulphate. copper chloride ,copper bromide, copper iodide, copper nitrate, copper sulphate.
Keratolytics - salicylic acid , lactic acid, nitric acid, pyruvic acid,oxalic acid, trichloro acetic acid, phenol, resorcinol,urea .
The solvents and penetration enhancers of the ingredients - Water, ethanol, dimethyl sulfoxide, propylene glycol, glycerol.
Patients with skin lesions that after clinical diagnosis are usually treated by dermatologists with destructive modalities without an histological evaluation will be included in the study. The clinical diagnoses include viral warts, seborrheic warts, skin tags, solar keratoses, fibromata and hemangiomata.
The treated lesions will be located on the trunk and limbs. Lesions on the face will not be included in the study.
The formulations will be infiltrated intra-dermally into the lesions in a maximal volume not exceeding 0.05 ml.
After the achievement of the desired local fixation effect, the lesions will be examined by a pathologist.
The patients will be closely followed-up during the procedure and the degree of possible associated pain will be evaluated. Possible local infection and the degree of scarring will be evaluated until complete healing of the treated area will occur.
The histological result will be informed to the patients.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01176994
|Hillel Yaffe Medical Center||Not yet recruiting|
|Hadera, Israel, 38100|
|Contact: Michael Kahana, MD 972-4-630-4667 email@example.com|
|Principal Investigator: Michael Kahana, MD|
|Sub-Investigator: Rafael Ezra, MSc Pharm|